Amgen announces $13.4bn acquisition of Celgene psoriasis treatment

27-08-2019

Saman Javed

Amgen announces $13.4bn acquisition of Celgene psoriasis treatment

Amgen has entered into an agreement with Celgene to acquire worldwide rights to Otezla (apremilast), the only oral, non-biologic treatment for psoriasis and psoriatic arthritis, for $13.4 billion.


Celgene, Amgen, psoriasis, apremilast, otezla, arthritis, acquisition, patent, biosimilar, biologic, inflammation, disease

LSIPR